Ads
related to: is provigil right for me- Support and Resources
Learn About XYWAV Treatment
Support and Resources.
- XYWAV Treatment
Learn About XYWAV Treatment & See
If it's The Right Option for You.
- Understanding XYWAV
Learn How XYWAV May Be
Individualized for You.
- XYWAV Patient Brochure
Learn Important Information
About Your XYWAV Treatment.
- Support and Resources
Search results
Results From The WOW.Com Content Network
Provigil was initially approved to treat excessive daytime sleepiness resulting from narcolepsy, and later approved the drug for further label indications. Cephalon allegedly promoted Provigil for a five-year period as a non-stimulant drug for the treatment of sleepiness, tiredness, decreased activity, lack of energy, and fatigue.
Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant and eugeroic (wakefulness promoter) medication used primarily to treat narcolepsy, [3] [8] [15] a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. [16]
The pharmaceutical company Cephalon, the original United States market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic. [25]
The clinic also spent nearly $100,000 during that period on Provigil, a stimulant that is “55 times more expensive than the generic equivalent,” the report said.
Provigil - used to treat excessive sleepiness and narcolepsy Prozac ( fluoxetine ) – an antidepressant of the SSRI class Luminal ( phenobarbital ) – a barbiturate with sedative and hypnotic properties
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...
MAID is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year.
Idiopathic hypersomnia (IH) is a neurological disorder which is characterized primarily by excessive sleep and excessive daytime sleepiness (EDS). [1] Idiopathic hypersomnia was first described by Bedrich Roth in 1976, and it can be divided into two forms: polysymptomatic and monosymptomatic.